Literature DB >> 29587045

Mean Rank, Equipercentile, and Regression Mapping of World Health Organization Quality of Life Brief (WHOQOL-BREF) to EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L) Utilities.

Hwee Lin Wee1,2, Khung Keong Yeo3,4, Kok Joon Chong5, Eric Yin Hao Khoo5,6, Yin Bun Cheung7,8.   

Abstract

BACKGROUND: Existing methods to link preference-based and profile-based health-related quality of life (HRQoL) questionnaires have their limitations. Hence, we developed a new mapping method (the mean rank method, MRM) and applied it to map the World Health Organization Quality of Life Questionnaire (WHOQOL-BREF) to the EuroQoL 5 Dimensions 5 Levels (EQ-5D-5L). We then compared the new MRM with current methods; i.e., regression-mapped (OLS method) and equipercentile method (EPM).
METHODS: Singapore residents, aged ≥21 y, were recruited from the general population and 2 outpatient clinics in acute care hospitals. Performance of the MRM was evaluated using both simulation and split-sample validation ( n = 658 in training and n = 657 in validation samples). Using the training sample, we derived 3 sets of mapped EQ-5D-5L utilities based on MRM, OLS method and EPM. Using simulation and the validation sample, we compared the performance of the mapping methods in terms of distribution parameters, mean utility by strata, association with health covariates, and prediction errors at the individual level, among others.
RESULTS: The WHOQOL-BREF Physical Health domain is the only domain significantly associated with EQ-5D-5L utilities. Simulation showed that MRM more accurately reproduced the variance and percentiles of the distribution of the observed utilities than did the OLS method or EPM. OLS method tended to underestimate the mean utility of good health states, overestimate the mean utility of poor health states, and underestimate the association with covariates. An analysis of validation sample gave similar results.
CONCLUSION: In scenarios similar to the mapping of WHOQOL-BREF to the EQ-5D-5L, the MRM outperformed the OLS method and EPM in important-though not all-aspects. The simplicity and reproducibility of the MRM makes it an attractive alternative to current methods.

Entities:  

Keywords:  health-related quality of life; linking values; mapping functions; patient-reported outcomes; preference-based measures

Mesh:

Year:  2018        PMID: 29587045     DOI: 10.1177/0272989X18756890

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  5 in total

1.  Mapping the Alzheimer's Disease Cooperative Study-Activities of Daily Living Inventory to the Health Utility Index Mark III.

Authors:  Yin Bun Cheung; Hui Xing Tan; Vivian Wei Wang; Nagaendran Kandiah; Nan Luo; Gerald C H Koh; Hwee Lin Wee
Journal:  Qual Life Res       Date:  2018-09-01       Impact factor: 4.147

2.  Mapping the Shah-modified Barthel Index to the Health Utility Index Mark III by the Mean Rank Method.

Authors:  Yin Bun Cheung; Hui Xing Tan; Nan Luo; Hwee Lin Wee; Gerald C H Koh
Journal:  Qual Life Res       Date:  2019-07-27       Impact factor: 4.147

3.  Mapping the medical outcomes study HIV health survey (MOS-HIV) to the EuroQoL 5 Dimension (EQ-5D-3 L) utility index.

Authors:  Yuan Shi; Jennifer Thompson; A Sarah Walker; Nicholas I Paton; Yin Bun Cheung
Journal:  Health Qual Life Outcomes       Date:  2019-05-10       Impact factor: 3.186

4.  Assessing the severity of functional impairment of psychiatric disorders: equipercentile linking the mini-ICF-APP and CGI.

Authors:  Stephan T Egger; Godehard Weniger; Mario Müller; Julio Bobes; Erich Seifritz; Stefan Vetter
Journal:  Health Qual Life Outcomes       Date:  2019-11-19       Impact factor: 3.186

5.  Mapping Dermatology Life Quality Index (DLQI) scores to EQ-5D utility scores using data of patients with atopic dermatitis from the National Health and Wellness Study.

Authors:  Andreas Westh Vilsbøll; Nana Kragh; Julie Hahn-Pedersen; Cathrine Elgaard Jensen
Journal:  Qual Life Res       Date:  2020-04-15       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.